Lemborexant

Research use only, not for human use.

An orally active, potent, selective, dual Orexin receptor OX1/2 antagonist with binding Ki of 6/3 nM, respectively.

An orally active, potent, selective, dual Orexin receptor OX1/2 antagonist with binding Ki of 6/3 nM, respectively; exhibits an overall improvement in properties such as the TDI of CYP3A and aqueous solubility, high OXRs antagonist activity and sufficient brain penetration; demonstrates high efficacy in preclinical sleep experiments.Sleep Disorder Phase 3 Clinical.

——

——

E-2006 | E2006

GPCR/G Protein

Orexin Receptor

Orexin Receptor

Neurological Disease

Sleep Disorder

1369764-02-2

410.4166

C22H20F2N4O2

>98% (HPLC)

DMSO: ≥ 30 mg/mL

O=C([C@H]1[C@@](C2=CC=CC(F)=C2)(COC3=CN=C(C)N=C3C)C1)NC4=NC=C(F)C=C4

Cyclopropanecarboxamide, 2-[[(2,4-dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-, (1R,2S)-

(-20℃)

With Ice Pack

≥ 2 years